Skip to main content
OpenTrials
Completed

NCT Number: NCT06338111

Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department

This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Syndrome Biomarker Disease Attributes Emergencies Emergency Department Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Cluj County Hospital Emergency Department

Cluj-Napoca, Cluj, 400006, Romania

About this study

The levels of the specified biomarkers were measured upon patient arrival at the Emergency Department (ED) and analyzed their correlation with 28-day mortality. The values of these biomarkers were monitored over the initial three days following admission to the ED, aiming to explore their potential in guiding the de-escalation of antibiotic treatment. Considering their prognostic significance, the main goal is to develop a novel scoring system tailored for use in the emergency department setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sepsis 3 Criteria

Exclusion criteria

  • individuals aged under 18 or above 90
  • pregnant women
  • individuals in custody or deprived of their liberty
  • patients with associated pathologies such as severe trauma
  • other types of shocks
  • acute stroke
  • burns
  • pancreatitis myocardial infarction, pulmonary edema, status asthmatics, convulsions, drug overdose, those requiring emergency surgery
  • terminal stage of neoplastic disease

Treatment and study plan

ELISA Sepsis Biomarkers dosage

Diagnostic Test

Observational

Other names: ELISA Specific Sepsis Biomarkers dosage

Primary outcomes

  1. Can we better predict mortality in septic patients from the Emergency Department?

    Time frame: 03.2024-05.2024

    Evaluation of the prognostic role of : IL-6, sTREM-1, suPAR, AZU1, hsPCR and PCT in predicting 28-day mortality in Emergency Department

Sponsors and collaborators

Lead sponsor

Iuliu Hatieganu University of Medicine and Pharmacy

Other

Registry information

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Mar 29, 2024
Registry last updated
Jun 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.